Salinosporamide A
CAS: 437742-34-2
Ref. 3D-FS36376
| 25µg | Discontinued | ||
| 50µg | Discontinued | ||
| 100µg | Discontinued | ||
| 250µg | Discontinued | ||
| 500µg | Discontinued |
Product Information
- (1R,4R,5S)-4-(2-Chloroethyl)-1-[(S)-(1S)-2-cyclohexen-1-ylhydroxymethyl]-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione
- (-)-Salinosporamide A
- NPI 0052
- 6-Oxa-2-azabicyclo[3.2.0]heptane-3,7-dione, 4-(2-chloroethyl)-1-[(S)-(1S)-2-cyclohexen-1-ylhydroxymethyl]-5-methyl-, (1R,4R,5S)-
Salinosporamide A is a novel anti-cancer compound that belongs to the class of aldol cyclization reaction. It is an irreversible inhibitor of protein kinase C and has been shown to inhibit growth factor-induced cell proliferation in vitro. Salinosporamide A also inhibits the production of nitric oxide, which may be involved in the inhibition of growth factor-induced cell proliferation in vitro. Salinosporamide A is selective for cAMP-dependent protein kinase, but not for other protein kinases such as Ca2+/calmodulin-dependent protein kinase II and Ca2+/calmodulin-dependent protein kinase IV. Salinosporamide A has also shown effectiveness against infectious diseases caused by bacteria and fungi. It acts by inhibiting the synthesis of DNA, RNA, and proteins.
